Industry sponsored bias in cost effectiveness analyses

BMJ

Volumn 342, Issue 7787, 2011, Pages 4-

  John Baptiste, Ava ^a   Bell, Chaim ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; EDITORIAL; GOVERNMENT; HEALTH CARE POLICY; INDUSTRY; INSURANCE; MEDICAL LITERATURE; PEER REVIEW; PHARMACOECONOMICS; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT;

EID: 78650781920     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c5350     Document Type: Editorial

References (10)

1. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699-703.
2. Miners AH, Garau M, Fidan D, Fischer AJ. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005;330:65.
3. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care 2010;26:330-3.
4. DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 2001;19:753-66.
5. Miller P. Role of pharmacoeconomic analysis in R&D decision making: when, where, how? Pharmacoeconomics 2005;23:1-12.
6. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000;19:92-109.
7. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-70.
8. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
9. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:355-71.
10. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-5.